## SECTION V - CERTAINTY OF EVIDENCE (CINeMA Framework)

**Assessment Scale:**  
- **No Concerns**: Minimal issues unlikely to meaningfully alter conclusions  
- **Some Concerns**: Moderate issues that may affect interpretation  
- **Major Concerns**: Serious issues that substantially undermine confidence  

### 39. Domain 1: Within-Study Bias (Risk of Bias)

| Item | Assessment Criterion                                                                                                            | Rating...                                                                                                                                                       | Evidence/Comments |
| ---- | ------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------------- |
| 39.1 | **RoB Distribution**: What proportion of evidence comes from studies at low vs. high risk of bias?                              | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |
| 39.2 | **Contribution-Weighted RoB**: Using contribution matrix, how much do high-RoB studies contribute to each treatment comparison? | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |
| 39.3 | **Domain-Specific Bias**: Are there particular bias domains (allocation concealment, blinding, attrition) of concern?           | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |
| 39.4 | **Indirect Evidence RoB**: For comparisons relying on indirect evidence, is RoB adequately low in contributing studies?         | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |

**Overall Rating for Within-Study Bias:** 
- <input type="checkbox" unchecked id="ca5248"> No concerns  
- <input type="checkbox" unchecked id="57bf61"> Some concerns  
- <input type="checkbox" unchecked id="adb4a4"> Major concerns

### 40. Domain 2: Reporting Bias (Publication & Selective Reporting Bias)

| Item | Assessment Criterion                                                                                                                     | Rating.....                                                                                                                                                     | Evidence/Comments |
| ---- | ---------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------------- |
| 40.1 | **Small-Study Effects**: Is there evidence of small-study effects (comparison-adjusted funnel plot asymmetry)?                           | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |
| 40.2 | **Unpublished Studies**: Were efforts made to identify unpublished studies? Were any found?                                              | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |
| 40.3 | **Protocol Registration**: Were trials registered prospectively with outcomes pre-specified?                                             | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |
| 40.4 | **Selective Outcome Reporting**: Is there evidence of selective outcome reporting within included studies?                               | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |
| 40.5 | **Network Geometry Suspicion**: Does network geometry suggest possible reporting bias (e.g., many small trials on specific comparisons)? | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |

**Overall Rating for Reporting Bias:** 
- <input type="checkbox" unchecked id="ca5248"> No concerns  
- <input type="checkbox" unchecked id="57bf61"> Some concerns  
- <input type="checkbox" unchecked id="adb4a4"> Major concerns

### 41. Domain 3: Indirectness

| Item | Assessment Criterion                                                                                                           | Rating.....                                                                                                                                                     | Evidence/Comments |
| ---- | ------------------------------------------------------------------------------------------------------------------------------ | --------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------------- |
| 41.1 | **Population Indirectness**: Do trial populations differ from target population in important characteristics?                  | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |
| 41.2 | **Intervention Indirectness**: Do trial interventions differ from those of interest (dose, formulation, co-treatments)?        | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |
| 41.3 | **Comparator Indirectness**: Do trial comparators differ from relevant clinical practice?                                      | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |
| 41.4 | **Outcome Indirectness**: Are outcomes surrogate markers rather than patient-important outcomes?                               | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |
| 41.5 | **Setting Indirectness**: Do trial settings differ from decision context (country, care level, time period)?                   | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |
| 41.6 | **Contribution-Weighted Indirectness**: Using contribution matrix, how much do indirect studies contribute to each comparison? | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |

**Overall Rating for Indirectness:** 
- <input type="checkbox" unchecked id="ca5248"> No concerns  
- <input type="checkbox" unchecked id="57bf61"> Some concerns  
- <input type="checkbox" unchecked id="adb4a4"> Major concerns

### 42. Domain 4: Imprecision

| Item | Assessment Criterion                                                                                                                                             | Rating.....                                                                                                                                                     | Evidence/Comments |
| ---- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------------- |
| 42.1 | **Sample Size**: Is the total sample size (events) adequate for the comparison?                                                                                  | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |
| 42.2 | **Confidence Interval Width**: Are confidence intervals sufficiently narrow to inform decision-making?                                                           | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |
| 42.3 | **Clinical Decision Thresholds**: Does the CI exclude clinically important benefit/harm in both directions, or does it include both meaningful benefit and harm? | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |
| 42.4 | **Equivalence Range**: If defining equivalence range (0.8-1.25 for OR), does the CI fall entirely within, cross, or lie outside this range?                      | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |
| 42.5 | **Optimal Information Size**: Has optimal information size been calculated and achieved?                                                                         | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |

**CINeMA Imprecision Rule:**  
- **No Concerns**: CI excludes no effect and does not cross clinical decision threshold  
- **Some Concerns**: CI crosses no effect but does not include clinically important harm/benefit in opposite direction  
- **Major Concerns**: CI includes both clinically important benefit and harm

**Overall Rating for Imprecision:** 
- <input type="checkbox" unchecked id="ca5248"> No concerns  
- <input type="checkbox" unchecked id="57bf61"> Some concerns  
- <input type="checkbox" unchecked id="adb4a4"> Major concerns

### 43. Domain 5: Heterogeneity

| Item | Assessment Criterion                                                                                                  | Rating...                                                                                                                                                       | Evidence/Comments |
| ---- | --------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------------- |
| 43.1 | **Heterogeneity Magnitude**: What is the magnitude of between-study heterogeneity (τ² or τ)?                          | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |
| 43.2 | **Prediction Interval**: Does the 95% prediction interval include both important benefit and harm?                    | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |
| 43.3 | **Clinical Importance**: Is heterogeneity clinically meaningful (does τ approach or exceed average treatment effect)? | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |
| 43.4 | **Heterogeneity Explanation**: Can heterogeneity be explained by known effect modifiers or study characteristics?     | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |
| 43.5 | **I² Statistic**: What is the I² value for the comparison network?                                                    | Value: ____%                                                                                                                                                    |                   |

**CINeMA Heterogeneity Rule:**  
- **No Concerns**: Prediction interval entirely within equivalence range or entirely favors one intervention  
- **Some Concerns**: Prediction interval crosses equivalence boundary but does not include clinically important effect in opposite direction  
- **Major Concerns**: Prediction interval includes clinically important benefit and harm

**Overall Rating for Heterogeneity:** 
- <input type="checkbox" unchecked id="ca5248"> No concerns  
- <input type="checkbox" unchecked id="57bf61"> Some concerns  
- <input type="checkbox" unchecked id="adb4a4"> Major concerns

### 44. Domain 6: Incoherence (Inconsistency)

| Item | Assessment Criterion                                                                                                                       | Rating.....                                                                                                                                                     | Evidence/Comments |
| ---- | ------------------------------------------------------------------------------------------------------------------------------------------ | --------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------------- |
| 44.1 | **Loop Inconsistency**: Are there loops in the network with statistically significant inconsistency (p < 0.05)?                            | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |
| 44.2 | **Direct vs. Indirect Disagreement**: Do direct and indirect estimates disagree meaningfully?                                              | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |
| 44.3 | **Inconsistency Factor**: What is the magnitude of inconsistency factors in affected loops?                                                | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |
| 44.4 | **Clinical Plausibility**: Is there clinical reason to expect different effects in different comparison contexts (transitivity violation)? | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |
| 44.5 | **Global Inconsistency**: Does global inconsistency testing (design-by-treatment interaction) suggest widespread inconsistency?            | <input type="checkbox" unchecked id="ca5248"> No <br><input type="checkbox" unchecked id="57bf61"> Some <br><input type="checkbox" unchecked id="adb4a4"> Major |                   |

**CINeMA Incoherence Rule:**  
- **No Concerns**: Direct and indirect estimates agree; both favor same intervention relative to equivalence  
- **Some Concerns**: Direct and indirect point estimates disagree but CIs overlap substantially  
- **Major Concerns**: Direct and indirect estimates favor opposite interventions with minimal CI overlap

**Overall Rating for Incoherence:** 
- <input type="checkbox" unchecked id="ca5248"> No concerns  
- <input type="checkbox" unchecked id="57bf61"> Some concerns  
- <input type="checkbox" unchecked id="adb4a4"> Major concerns

### 45. Overall Confidence Rating

Based on judgments across all six CINeMA domains, rate overall confidence in NMA results for each treatment comparison:

| Comparison        | Overall Confidence                                                                                                                                                                                                    | Justification |
| ----------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------- |
| Treatment A vs. B | <input type="checkbox" unchecked id="85195b"> High  <input type="checkbox" unchecked id="85195b"> Moderate  <input type="checkbox" unchecked id="85195b"> Low  <input type="checkbox" unchecked id="85195b"> Very Low |               |
| Treatment A vs. C | <input type="checkbox" unchecked id="85195b"> High  <input type="checkbox" unchecked id="85195b"> Moderate  <input type="checkbox" unchecked id="85195b"> Low  <input type="checkbox" unchecked id="85195b"> Very Low |               |
| Treatment B vs. C | <input type="checkbox" unchecked id="85195b"> High  <input type="checkbox" unchecked id="85195b"> Moderate  <input type="checkbox" unchecked id="85195b"> Low  <input type="checkbox" unchecked id="85195b"> Very Low |               |

**Confidence Levels Defined:**
- **High**: Very confident that true effect lies close to estimate  
- **Moderate**: Moderately confident; true effect likely close to estimate but possibly substantially different  
- **Low**: Limited confidence; true effect may be substantially different from estimate  
- **Very Low**: Very little confidence; true effect likely substantially different from estimate

**Downgrading Logic:**
- Start at **High** (for RCT networks)  
- Downgrade one level for **each domain** with "Some Concerns"  
- Downgrade two levels for **each domain** with "Major Concerns"  
- Can downgrade at most three levels total

---
